Peptide News Digest

CordenPharma's AmbioPharm Subsidiary $120M Aiken County Peptide Expansion, Barclays Lifts Hims & Hers PT $29→$39 on Peptide Catalyst, Frontiers Cell-Penetrating Peptide Diabetes Delivery Paper, PCAC + 503B Deadlines 11-12 Days Out, AHA/ACC First-Ever CKM Syndrome Guideline, Ohio State Board Peptide Compounding Guidance, Hanmi HM500197 First Peptide-Based Myostatin Inhibitor at ADA 2026

AmbioPharm $120M SC peptide expansion, Barclays raises Hims to $39, Frontiers CPP diabetes delivery, PCAC/503B 11-12 days, AHA/ACC CKM guideline, Ohio + Hanmi.

7 stories · Covering industry, research, regulatory, clinical-trials

Editor's Note

A quieter mid-week post-conference day with seven substantive peptide-field signals once we surface backdated items worth catching up on. AmbioPharm, now a CordenPharma subsidiary after the May 27 acquisition close, announced a $118.96 million Aiken County, South Carolina manufacturing expansion on June 16, adding a 68,000-square-foot modular building and 200-plus jobs. Barclays raised its Hims & Hers (NYSE: HIMS) price target to $39 from $29 on June 17 (Overweight rating) citing Novo Nordisk partnership momentum and the peptide-catalyst opportunity beyond 2027; HIMS gained roughly 6% on the day. Frontiers in Pharmacology published June 18 a review of cell-penetrating peptides and peptide nucleic acids as targeted-delivery vehicles for diabetes treatment. The regulatory countdown moved into single-digit-week range: the FDA's 503B GLP-1 comment window closes June 29 (11 days), and PCAC oral-presentation requests close June 30 (12 days). Three backdated items worth surfacing today: AHA/ACC/ADA/ASN published the first-ever Cardiovascular-Kidney-Metabolic (CKM) Syndrome guideline on June 9, 2026 in Circulation and JACC, embedding GLP-1 RAs as a recommended therapy for select T2D and obesity patients with CV risk; the Ohio State Board of Pharmacy updated its peptide compounding guidance on February 18, 2026, layering state-level enforcement on top of federal rules in a pattern that now parallels the Alabama Board notice we covered yesterday; and Hanmi Pharmaceutical unveiled HM500197 (LA-MSTN) at ADA 2026 as the world's first peptide-based myostatin inhibitor, positioned as a muscle-preserving adjunct to GLP-1 weight-loss therapy.

Industry

AmbioPharm (Now a CordenPharma Subsidiary) Announces $118.96M Aiken County Peptide Manufacturing Expansion With 200+ Jobs

AmbioPharm announced June 16 a $118.96 million expansion of its Aiken County, South Carolina headquarters, adding a 68,000-square-foot modular manufacturing building at its existing 1024 Dittman Court campus in North Augusta and creating more than 200 new jobs. The facility will offer commercial-scale GMP synthesis including solid-phase peptide synthesis (SPPS), liquid-phase peptide synthesis (LPPS), and hybrid approaches, mirroring upgrades made to AmbioPharm's Shanghai facility. Operations target end of 2027. The announcement arrives roughly three weeks after the May 27, 2026 close of CordenPharma's acquisition of AmbioPharm, which secured CordenPharma a second US peptide site (joining Boulder, Colorado) and its first Shanghai-based supply node. AmbioPharm shareholders are reinvesting in the combined entity. The expansion is the largest single US peptide-manufacturing capacity addition of 2026 to date.

#ambiopharm #cordenpharma #peptide-manufacturing #aiken-county #south-carolina #spps #manufacturing-expansion #peptide-api
Industry

Barclays Raises Hims & Hers (HIMS) Price Target to $39 From $29 on Novo Partnership Momentum and Peptide-Catalyst Opportunity

Barclays raised its price target on Hims & Hers Health (NYSE: HIMS) to $39 from $29 on June 17, citing improved customer-momentum signals from alternative data since the March 9 Novo Nordisk collaboration announcement and the upcoming peptide-catalyst opportunity tied to the July 23-24 PCAC meeting. The firm maintained an Overweight rating; the $39 target implies roughly 21% upside from the prior close. HIMS gained about 6% on the day. Leerink reiterated Market Perform with a $25 PT ahead of the same PCAC meeting, framing potential PCAC approval as an upside catalyst for Hims' growth outlook beyond 2027. Hims acquired a California peptide manufacturing facility in 2025 and added in-house lab testing capacity ahead of the regulatory window.

#hims-and-hers #barclays #leerink #analyst-coverage #novo-nordisk #pcac #peptide-catalyst
Research

Frontiers in Pharmacology (June 18): Review of Cell-Penetrating Peptides and Peptide Nucleic Acids for Targeted Diabetes Drug Delivery

Frontiers in Pharmacology published June 18 a review on enhancing diabetes treatment through targeted nucleic acid and drug delivery using cell-penetrating peptides (CPPs), peptide nucleic acids (PNAs), and receptor targeting. The paper maps how CPPs can shuttle therapeutic cargo across cellular membranes in pancreatic-beta-cell and insulin-resistance contexts and how PNAs can modulate gene expression in diabetic targets, addressing the persistent delivery problem that limits peptide and oligonucleotide therapy. The review framing intersects with the broader push toward oral peptide delivery (Entera Bio EB613, Foundayo) and platform-driven peptide-conjugate therapeutics (Bicycle, Parabilis Medicines, MultiValent Biotherapeutics) reshaping the obesity, diabetes, and oncology spaces in 2026.

#frontiers-in-pharmacology #cell-penetrating-peptides #peptide-nucleic-acids #diabetes #drug-delivery #peptide-platform
Regulatory

FDA 503B GLP-1 Comment Window Closes in 11 Days (June 29); PCAC Oral-Presentation Requests Close in 12 Days (June 30)

The two near-term peptide regulatory deadlines moved into the single-digit-week window on June 18. The FDA's April 30 proposed rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list closes its 60-day comment window on June 29, after which the agency will weigh comments and issue final rulemaking; once final, the rule blocks 503B outsourcing facilities from bulk-compounding the molecules even under future shortage designation. Separately, requests to make oral presentations at the July 23-24 PCAC peptide-compounding advisory committee close June 30; the committee will weigh BPC-157, KPV, TB-500, MOTs-c, DSIP (Emideltide), Semax, and Epitalon for 503A bulk-substances-list inclusion. Written PCAC comments remain open through July 9.

#fda #503b #pcac #comment-window #compounding #semaglutide #tirzepatide #bpc-157
Research

First-Ever AHA/ACC/ADA/ASN Cardiovascular-Kidney-Metabolic (CKM) Syndrome Guideline (June 9, 2026): GLP-1 Therapies Embedded as Recommended Care

The American College of Cardiology, American Heart Association, American Diabetes Association, and American Society of Nephrology jointly published the first-ever clinical guideline for Cardiovascular-Kidney-Metabolic (CKM) Syndrome on June 9, 2026, in Circulation and JACC. The framework establishes a standardized CKM staging system (stages 0 to 4) to identify patients earlier, personalize therapy by absolute cardiovascular risk, and promote both prevention and regression of disease. GLP-1 receptor agonists are explicitly recommended in select patients with type 2 diabetes or obesity plus other cardiovascular risk factors, alongside SGLT2 inhibitors and kidney-protective therapies. The guideline embeds the GLP-1 class into multi-society standard of care for the first time and adds clinical-society weight to the SELECT, FLOW, and ESSENCE outcomes evidence base.

#aha #acc #ada #asn #ckm-syndrome #clinical-guideline #glp-1 #sglt2 #cardiovascular #kidney
Regulatory

Ohio State Board of Pharmacy February 2026 Update Sets State-Level Peptide Compounding Guardrails Alongside Federal 503A Rules

The Ohio State Board of Pharmacy released a February 18, 2026 update to its peptide compounding guidance establishing state-specific requirements that layer on top of federal 503A rules. The Ohio guidance requires all compounded peptides to be prepared pursuant to a valid patient-specific prescription from an Ohio-licensed practitioner, with detailed prescription documentation and provider-verification protocols; pharmacies cannot compound peptides on the FDA list of substances withdrawn for safety or effectiveness reasons. The guidance followed late-2025 and early-2026 enforcement actions in which at least three Ohio pharmacies received consent agreements and fines for peptide compounding violations. Together with the Alabama Board of Medical Examiners' May 26 notice prohibiting non-FDA-approved peptide prescribing, Ohio's update establishes a clear state-level enforcement pattern ahead of the July 23-24 PCAC meeting.

#ohio #state-board-of-pharmacy #state-medical-board #peptide-compounding #503a #enforcement #research-grade-peptides
Clinical Trials

Hanmi Pharmaceutical Unveils HM500197 (LA-MSTN) at ADA 2026 as the World's First Peptide-Based Myostatin Inhibitor for GLP-1 Muscle-Loss Adjunct Use

Hanmi Pharmaceutical presented HM500197 (LA-MSTN) at ADA 2026 (June 5-8, New Orleans) as the world's first peptide-based myostatin inhibitor, positioned as a muscle-preserving adjunct to GLP-1 weight-loss therapy. The molecule was designed on Hanmi's HARP (Hanmi AI-driven Research Platform) integrating AI and structural modeling. Hanmi paired the LA-MSTN unveiling with a second next-generation candidate, HM17321, in a broader eight-abstract slate spanning the company's obesity pipeline. The myostatin angle addresses a major shortcoming of the current GLP-1 class — 25-40% of weight loss coming from lean tissue rather than fat — which Stanford's Maharjan team flagged at ENDO 2026 with the 560-step daily activity drop and which underlies the broader bone-health and frailty concerns now being studied across the GLP-1 class.

#hanmi #hm500197 #la-mstn #myostatin #peptide-myostatin-inhibitor #muscle-preservation #ada-2026 #korea #harp-ai-platform